Does the media prefer OXB or ONT?

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 1 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.34 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Biomedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Nanopore Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SLN or OXB?

Oxford Biomedica has a consensus price target of GBX 613.32, suggesting a potential upside of 17.72%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Does the media prefer AVCT or OXB?

In the previous week, Avacta Group had 3 more articles in the media than Oxford Biomedica. MarketBeat recorded 4 mentions for Avacta Group and 1 mentions for Oxford Biomedica. Avacta Group's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avacta Group 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oxford Biomedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OXB or HZD?

Oxford Biomedica currently has a consensus price target of GBX 613.32, suggesting a potential upside of 17.72%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, research analysts clearly believe Oxford Biomedica is more favorable than Horizon Discovery Group plc (HZD.L). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Horizon Discovery Group plc (HZD.L) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, PRTC or OXB?

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health £6.37M 42.76 -£91.86M N/A N/A Oxford Biomedica £175.36M 3.60 -£143.51M -£31.96 N/A

Does the media favor PRTC or OXB?

In the previous week, PureTech Health had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 3 mentions for PureTech Health and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Oxford Biomedica is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Oxford Biomedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oxford Biomedica (OXB) Competitors

GBX 538 +17.00 (+3.26%)

As of 08:29 AM Eastern

Compare

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

Should you buy Oxford Biomedica stock or one of its competitors? Oxford Biomedica's main competitors and comparable companies include Oxford Nanopore Technologies (ONT), Silence Therapeutics (SLN), Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), and PureTech Health (PRTC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Biomedica (LON:OXB) and Oxford Nanopore Technologies (LON:ONT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Oxford Biomedica has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£175.36M	3.60	-£143.51M	-£31.96	N/A
Oxford Nanopore Technologies	£235M	8.71	-£175.21M	-£12.50	N/A

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 18.3% of Oxford Nanopore Technologies shares are owned by institutional investors. 25.8% of Oxford Biomedica shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Oxford Biomedica has a net margin of -23.23% compared to Oxford Nanopore Technologies' net margin of -54.66%. Oxford Nanopore Technologies' return on equity of -35.45% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-23.23%	-54.51%	-12.67%
Oxford Nanopore Technologies	-54.66%	-35.45%	-14.42%

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 1 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.34 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oxford Biomedica has a beta of 1.092, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.871, suggesting that its share price is 13% less volatile than the broader market.

Oxford Biomedica currently has a consensus price target of GBX 613.32, indicating a potential upside of 17.72%. Oxford Nanopore Technologies has a consensus price target of GBX 198.60, indicating a potential downside of 5.03%. Given Oxford Biomedica's higher possible upside, research analysts plainly believe Oxford Biomedica is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Oxford Biomedica and Oxford Nanopore Technologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Oxford Biomedica has a consensus price target of GBX 613.32, suggesting a potential upside of 17.72%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Silence Therapeutics has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Oxford Biomedica	£175.36M	3.60	-£143.51M	-£31.96	N/A

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -23.23%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Oxford Biomedica	-23.23%	-54.51%	-12.67%

32.4% of Oxford Biomedica shares are held by institutional investors. 25.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Oxford Biomedica had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Oxford Biomedica	Neutral

Summary

Oxford Biomedica beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Oxford Biomedica compare to Avacta Group?

Avacta Group (LON:AVCT) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Oxford Biomedica has a net margin of -23.23% compared to Avacta Group's net margin of -35,730.97%. Oxford Biomedica's return on equity of -54.51% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-35,730.97%	-1,293.07%	-21.80%
Oxford Biomedica	-23.23%	-54.51%	-12.67%

Avacta Group presently has a consensus target price of GBX 99, suggesting a potential upside of 51.15%. Oxford Biomedica has a consensus target price of GBX 613.32, suggesting a potential upside of 17.72%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts plainly believe Avacta Group is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Avacta Group had 3 more articles in the media than Oxford Biomedica. MarketBeat recorded 4 mentions for Avacta Group and 1 mentions for Oxford Biomedica. Avacta Group's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avacta Group	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.092, meaning that its stock price is 9% more volatile than the broader market.

Avacta Group has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,648.76	-£30.08M	-£9.24	N/A
Oxford Biomedica	£175.36M	3.60	-£143.51M	-£31.96	N/A

2.9% of Avacta Group shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 47.7% of Avacta Group shares are held by company insiders. Comparatively, 25.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Avacta Group beats Oxford Biomedica on 9 of the 15 factors compared between the two stocks.

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Oxford Biomedica (LON:OXB) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Horizon Discovery Group plc (HZD.L) has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£175.36M	3.60	-£143.51M	-£31.96	N/A
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A

Oxford Biomedica currently has a consensus price target of GBX 613.32, suggesting a potential upside of 17.72%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, research analysts clearly believe Oxford Biomedica is more favorable than Horizon Discovery Group plc (HZD.L).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Horizon Discovery Group plc (HZD.L)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

32.4% of Oxford Biomedica shares are held by institutional investors. 25.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Oxford Biomedica's net margin of -23.23%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-23.23%	-54.51%	-12.67%
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A

In the previous week, Oxford Biomedica had 1 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Horizon Discovery Group plc (HZD.L). Oxford Biomedica's average media sentiment score of 0.00 equaled Horizon Discovery Group plc (HZD.L)'saverage media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Horizon Discovery Group plc (HZD.L)	Neutral

Summary

Oxford Biomedica beats Horizon Discovery Group plc (HZD.L) on 8 of the 12 factors compared between the two stocks.

How does Oxford Biomedica compare to PureTech Health?

PureTech Health (LON:PRTC) and Oxford Biomedica (LON:OXB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

In the previous week, PureTech Health had 2 more articles in the media than Oxford Biomedica. MarketBeat recorded 3 mentions for PureTech Health and 1 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.00 beat PureTech Health's score of -0.12 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oxford Biomedica	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.0% of PureTech Health shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by company insiders. Comparatively, 25.8% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

PureTech Health has higher earnings, but lower revenue than Oxford Biomedica.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£6.37M	42.76	-£91.86M	N/A	N/A
Oxford Biomedica	£175.36M	3.60	-£143.51M	-£31.96	N/A

PureTech Health has a beta of 0.771, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.092, suggesting that its stock price is 9% more volatile than the broader market.

PureTech Health has a net margin of 7.53% compared to Oxford Biomedica's net margin of -23.23%. PureTech Health's return on equity of 0.14% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	7.53%	0.14%	-13.39%
Oxford Biomedica	-23.23%	-54.51%	-12.67%

PureTech Health presently has a consensus target price of GBX 508, indicating a potential upside of 357.66%. Oxford Biomedica has a consensus target price of GBX 613.32, indicating a potential upside of 17.72%. Given PureTech Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

PureTech Health beats Oxford Biomedica on 8 of the 15 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£651.24M	£3.94B	£7.27B	£2.81B
Dividend Yield	4.57%	3.65%	2.53%	6.27%
P/E Ratio	-16.83	13.62	275.62	367.19
Price / Sales	3.71	1,185.60	583.29	88,572.78
Price / Cash	3.01	39.46	27.30	27.87
Price / Book	7.95	17.25	10.83	7.14
Net Income	-£143.51M	-£22.69M	£3.50B	£5.89B
7 Day Performance	-1.10%	-1.83%	-1.40%	0.22%
1 Month Performance	21.17%	-8.07%	-4.19%	-0.32%
1 Year Performance	-16.33%	14.10%	6.83%	22.75%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	1.9446 of 5 stars	GBX 538 +3.3%	GBX 613.32 +14.0%	-19.0%	£651.24M	£175.36M	N/A	891
ONT Oxford Nanopore Technologies	1.6292 of 5 stars	GBX 214.60 -1.4%	GBX 198.60 -7.5%	+42.6%	£2.10B	£235M	N/A	1,314	High Trading Volume
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume
AVCT Avacta Group	1.5817 of 5 stars	GBX 72 flat	GBX 99 +37.5%	-7.0%	£337.36M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

How does Oxford Biomedica compare to Avacta Group?

Summary

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Oxford Biomedica compare to PureTech Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. ONT, SLN, AVCT, HZD, and PRTC

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Which has higher earnings and valuation, OXB or ONT?

Do institutionals & insiders believe in OXB or ONT?

Is OXB or ONT more profitable?

Does the media prefer OXB or ONT?

Which has more risk and volatility, OXB or ONT?

Do analysts recommend OXB or ONT?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Do analysts prefer SLN or OXB?

Which has better earnings & valuation, SLN or OXB?

Is SLN or OXB more profitable?

Do insiders & institutionals have more ownership in SLN or OXB?

Does the media prefer SLN or OXB?

Summary

How does Oxford Biomedica compare to Avacta Group?

Is AVCT or OXB more profitable?

Do analysts prefer AVCT or OXB?

Does the media prefer AVCT or OXB?

Which has more risk & volatility, AVCT or OXB?

Which has stronger earnings and valuation, AVCT or OXB?

Do insiders and institutionals hold more shares of AVCT or OXB?

Summary

How does Oxford Biomedica compare to Horizon Discovery Group plc (HZD.L)?

Which has preferable earnings and valuation, OXB or HZD?

Do analysts prefer OXB or HZD?

Do insiders & institutionals have more ownership in OXB or HZD?

Is OXB or HZD more profitable?

Does the media prefer OXB or HZD?

Summary

How does Oxford Biomedica compare to PureTech Health?

Does the media favor PRTC or OXB?

Do institutionals and insiders believe in PRTC or OXB?

Which has preferable valuation and earnings, PRTC or OXB?

Which has more volatility & risk, PRTC or OXB?

Is PRTC or OXB more profitable?

Do analysts rate PRTC or OXB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools